Show simple item record

dc.contributor.authorMendel, Arielle
dc.contributor.authorBernatsky, Sasha
dc.contributor.authorPineau, Christian A
dc.contributor.authorSt-Pierre, Yvan
dc.contributor.authorHanly, John G
dc.contributor.authorUrowitz, Murray B
dc.contributor.authorClarke, Ann E
dc.contributor.authorRomero-Diaz, Juanita
dc.contributor.authorGordon, Caroline
dc.contributor.authorBae, Sang-Cheol
dc.contributor.authorWallace, Daniel J
dc.contributor.authorMerrill, Joan T
dc.contributor.authorBuyon, Jill
dc.contributor.authorIsenberg, David A
dc.contributor.authorRahman, Anisur
dc.contributor.authorGinzler, Ellen M
dc.contributor.authorPetri, Michelle
dc.contributor.authorDooley, Mary Anne
dc.contributor.authorFortin, Paul
dc.contributor.authorGladman, Dafna D
dc.contributor.authorSteinsson, Kristján
dc.contributor.authorRamsey-Goldman, Rosalind
dc.contributor.authorKhamashta, Munther A
dc.contributor.authorAranow, Cynthia
dc.contributor.authorMackay, Meggan
dc.contributor.authorAlarcón, Graciela
dc.contributor.authorManzi, Susan
dc.contributor.authorNived, Ola
dc.contributor.authorJönsen, Andreas
dc.contributor.authorZoma, Asad A
dc.contributor.authorvan Vollenhoven, Ronald F
dc.contributor.authorRamos-Casals, Manuel
dc.contributor.authorRuiz-Irastorza, Giuillermo
dc.contributor.authorLim, Sam
dc.contributor.authorKalunian, Kenneth C
dc.contributor.authorInanc, Murat
dc.contributor.authorKamen, Diane L
dc.contributor.authorPeschken, Christine A
dc.contributor.authorJacobsen, Søren
dc.contributor.authorAskanase, Anca
dc.contributor.authorSanchez-Guerrero, Jorge
dc.contributor.authorBruce, Ian N
dc.contributor.authorCostedoat-Chalumeau, Nathalie
dc.contributor.authorVinet, Evelyne
dc.date.accessioned2023-02-08T19:18:18Z
dc.date.available2023-02-08T19:18:18Z
dc.identifier.citationMendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón G, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet E. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology (Oxford). 2019 Jul 1;58(7):1259-1267. doi: 10.1093/rheumatology/kez014. PMID: 30753683; PMCID: PMC6821299.en_US
dc.identifier.eissn1462-0332
dc.identifier.doi10.1093/rheumatology/kez014
dc.identifier.pmid30753683
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8306
dc.description.abstractTo assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.
dc.description.abstractThis observational cohort study included premenopausal women ages 18-45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000-2017. World Health Organization Category 3 or 4 contraindications to CHCs (e.g. hypertension, aPL) were assessed at each study visit. High disease activity (SLEDAI score >12 or use of >0.5 mg/kg/day of prednisone) was considered a relative contraindication.
dc.description.abstractA total of 927 SLE women contributed 6315 visits, of which 3811 (60%) occurred in the presence of one or more possible contraindication to CHCs. Women used CHCs during 512 (8%) visits, of which 281 (55%) took place in the setting of one or more possible contraindication. The most frequently observed contraindications were aPL (52%), hypertension (34%) and migraine with aura (22%). Women with one or more contraindication were slightly less likely to be taking CHCs [7% of visits (95% CI 7, 8)] than women with no contraindications [9% (95% CI 8, 10)].
dc.description.abstractCHC use was low compared with general population estimates (>35%) and more than half of CHC users had at least one possible contraindication. Many yet unmeasured factors, including patient preferences, may have contributed to these observations. Further work should also aim to clarify outcomes associated with this exposure.
dc.language.isoenen_US
dc.relation.urlhttps://academic.oup.com/rheumatology/article/58/7/1259/5312899en_US
dc.rights© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectanti-phospholipid syndromeen_US
dc.subjectcontraceptionen_US
dc.subjectepidemiologyen_US
dc.subjectsystemic lupus erythematosusen_US
dc.titleUse of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleRheumatology (Oxford, England)en_US
dc.source.volume58
dc.source.issue7
dc.source.beginpage1259
dc.source.endpage1267
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryEngland
dc.description.versionVoRen_US
refterms.dateFOA2023-02-08T19:18:19Z
html.description.abstractTo assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.
html.description.abstractThis observational cohort study included premenopausal women ages 18-45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000-2017. World Health Organization Category 3 or 4 contraindications to CHCs (e.g. hypertension, aPL) were assessed at each study visit. High disease activity (SLEDAI score >12 or use of >0.5 mg/kg/day of prednisone) was considered a relative contraindication.
html.description.abstractA total of 927 SLE women contributed 6315 visits, of which 3811 (60%) occurred in the presence of one or more possible contraindication to CHCs. Women used CHCs during 512 (8%) visits, of which 281 (55%) took place in the setting of one or more possible contraindication. The most frequently observed contraindications were aPL (52%), hypertension (34%) and migraine with aura (22%). Women with one or more contraindication were slightly less likely to be taking CHCs [7% of visits (95% CI 7, 8)] than women with no contraindications [9% (95% CI 8, 10)].
html.description.abstractCHC use was low compared with general population estimates (>35%) and more than half of CHC users had at least one possible contraindication. Many yet unmeasured factors, including patient preferences, may have contributed to these observations. Further work should also aim to clarify outcomes associated with this exposure.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentRheumatologyen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalRheumatology (Oxford, England)


Files in this item

Thumbnail
Name:
kez014.pdf
Size:
284.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Except where otherwise noted, this item's license is described as © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.